Arca
Skip to content
Tools
Tools

KIT: Mast/stem cell growth factor receptor Kit

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis.

  • Drugs that act on it: 32
  • Approved: 12
  • In phases 1 to 3: 20
  • Sponsors: 24

Who Is On It, and How Far Along

Every drug ChEMBL records acting on KIT, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody
  • Other

Approved12

  • Regorafenib
  • Imatinib
  • Sorafenib
  • Sunitinib
  • Pazopanib
  • Quizartinib
  • Avapritinib
  • Midostaurin
  • Tivozanib
  • Ripretinib
  • Pexidartinib
  • Dasatinib anhydrous

Phase 310

  • Catequentinib
  • Famitinib
  • Cediranib
  • Motesanib
  • Masitinib
  • CM-082
  • Seralutinib
  • Dovitinib
  • Semaxanib
  • Vatalanib

Phase 29

  • Briquilimab
  • Amuvatinib
  • ENMD-2076
  • Foretinib
  • SU-014813
  • Tandutinib
  • Telatinib
  • XL-820
  • XL-999

Phase 11

  • OSI-930

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule2991%
  • Antibody13%
  • Other26%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Stem cell growth factor receptor inhibitor.
RegorafenibApprovedBayerSmall moleculeInhibitor—96Boxed warning
ImatinibApprovedNovartis PharmaceuticalsSmall moleculeInhibitor—84—
SorafenibApprovedBayerSmall moleculeInhibitor—62—
SunitinibApprovedCPPI CVSmall moleculeInhibitor—54Boxed warning
PazopanibApprovedNovartis PharmaceuticalsSmall moleculeInhibitor—27Boxed warning
QuizartinibApprovedDaiichi SankyoSmall moleculeInhibitor—17Boxed warning
AvapritinibApprovedSanofiSmall moleculeInhibitor—15—
MidostaurinApprovedNovartis PharmaceuticalsSmall moleculeInhibitor—15—
TivozanibApprovedLG ChemSmall moleculeInhibitor—8—
RipretinibApprovedOno PharmaceuticalSmall moleculeInhibitor—6—
PexidartinibApprovedDaiichi SankyoSmall moleculeInhibitor—3Boxed warning
Dasatinib anhydrousApprovedChia Tai Tianqing Pharmaceutical GroupSmall moleculeInhibitor—0—
CatequentinibPhase 3—Small moleculeInhibitor—183—
FamitinibPhase 3Jiangsu Hengrui MedicineSmall moleculeInhibitor—28—
CediranibPhase 3AstraZeneca PharmaceuticalsSmall moleculeInhibitor—18—
MotesanibPhase 3GERONSmall moleculeInhibitor—8—
MasitinibPhase 3AB ScienceSmall moleculeInhibitor—3—
CM-082Phase 3AnewPharmaOtherInhibitor—2—
SeralutinibPhase 3Gossamer Bio USA, Inc.Small moleculeInhibitor—1—
DovitinibPhase 3Novartis PharmaceuticalsSmall moleculeInhibitor—0—
SemaxanibPhase 3—Small moleculeInhibitor—0—
VatalanibPhase 3Novartis PharmaceuticalsSmall moleculeInhibitor—0—
BriquilimabPhase 2Jasper Therapeutics, Inc.AntibodyInhibitor—4—
AmuvatinibPhase 2Astex Pharmaceuticals, Inc.Small moleculeInhibitor—0—
ENMD-2076Phase 2CASI PharmaceuticalsSmall moleculeInhibitor—0—
ForetinibPhase 2GSKSmall moleculeInhibitor—0—
SU-014813Phase 2PfizerSmall moleculeInhibitor—0—
TandutinibPhase 2Takeda Pharmaceuticals USASmall moleculeInhibitor—0—
TelatinibPhase 2Taizhou EOC Pharma Co., Ltd.Small moleculeInhibitor—0—
XL-820Phase 2ExelixisOtherInhibitor—0—
XL-999Phase 2Symphony Evolution, Inc.Small moleculeInhibitor—0—
OSI-930Phase 1Astellas PharmaSmall moleculeInhibitor—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 116 in all, from ClinicalTrials.gov.
A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS)MotesanibPhase 4Not yet recruitingGeron Corporation2026-11-16
Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue SarcomaCatequentinibPhase 2RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University2026-11-05
Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesSunitinib—Enrolling by invitationChiyi Chen2026-11-03
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCTMotesanibPhase 1Not yet recruitingUniversity of Wisconsin, Madison2026-11-02
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal CarcinomaCatequentinibPhase 2Not yet recruitingSun Yat-sen University2026-10-29
Pucotenlimab and Anlotinib in Combination With ChemotherapyCatequentinibPhase 2RecruitingZhejiang Cancer Hospital2026-10-27
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLCFamitinibPhase 2Not yet recruitingRuijin Hospital2026-10-22
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPImatinibPhase 3Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.2026-10-21
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCCatequentinibPhase 2Not yet recruitingPeking University People's Hospital2026-10-21
Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaSunitinib, CatequentinibPhase 3Active, not recruitingSun Yat-sen University2026-10-20
Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)QuizartinibPhase 2Not yet recruitingNational Cancer Institute (NCI)2026-10-07
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)CatequentinibPhase 2RecruitingSun Yat-sen University2026-10-07
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2026-10-05
First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainPazopanib, Sunitinib, Tivozanib—Active, not recruitingBristol-Myers Squibb2026-10-01
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung CancerCatequentinibNot applicableNot yet recruitingZhejiang Cancer Hospital2026-09-30
Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic CholangiocarcinomaCatequentinibPhase 2Not yet recruitingFudan University2026-09-29
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialFamitinibPhase 2RecruitingThe First Affiliated Hospital with Nanjing Medical University2026-09-29
De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid LeukemiaImatinibPhase 4Not yet recruitingNanfang Hospital, Southern Medical University2026-09-24
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaSorafenibPhase 3RecruitingBeOne Medicines2026-09-23
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerFamitinibPhase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou University2026-09-11
Real-world Insight Into Systemic Therapies for HCC: Single-center StudySorafenib—RecruitingMansoura University2026-09-10
Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCFamitinibPhase 2RecruitingFirst Affiliated Hospital Xi'an Jiaotong University2026-08-31
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk OsteosarcomaSorafenibPhase 2RecruitingAnna Raciborska2026-08-26
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerRegorafenibPhase 2Not yet recruitingFujian Cancer Hospital2026-08-14
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2026-08-06
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanRegorafenibPhase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.2026-07-28
Hyperpolarized MRI for GIST on ImatinibImatinib—Not yet recruitingChang Gung Memorial Hospital2026-07-24
Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid LeukemiaMidostaurinPhase 1 / Phase 2Not yet recruitingUniversity Hospital, Bordeaux2026-07-24
IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRegorafenibPhase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.2026-07-23
DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AMLSorafenibPhase 3RecruitingThe Second Affiliated Hospital of Kunming Medical University2026-07-20
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat SyndromeRegorafenibPhase 2Not yet recruitingXiang-Qian2026-07-09
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibImatinib, Regorafenib, SunitinibPhase 2RecruitingGlaxoSmithKline2026-07-08
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian CancerSunitinibPhase 2RecruitingBai-Rong Xia2026-06-25
Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesFamitinibPhase 1 / Phase 2RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University2026-06-23
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsSorafenib—Active, not recruitingHarbin Medical University2026-06-12
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerFamitinibPhase 2Not yet recruitingHunan Cancer Hospital2026-06-04
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)ImatinibPhase 3RecruitingGlaxoSmithKline2026-05-13
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AMLMidostaurin, Sorafenib—Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology2026-05-07
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid TumorsRegorafenibPhase 1RecruitingWest China Hospital2026-05-05
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical IndomethacinSorafenibPhase 2RecruitingNational Taiwan University Hospital2026-05-01
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaImatinibPhase 2RecruitingVictoria Biomedical Research Institute2026-04-30
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in GermanyImatinib—RecruitingNovartis Pharmaceuticals2026-04-24
Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative NeoplasmsMotesanibPhase 2Not yet recruitingM.D. Anderson Cancer Center2026-04-24
Study of SA+X in the Treatment of Newly Diagnosed AMLQuizartinibPhase 2RecruitingRuijin Hospital2026-04-23
Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar PustulosisImatinibPhase 3Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine2026-04-15
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal MelanomaFamitinibPhase 2Not yet recruitingShanghai Zhongshan Hospital2026-04-08
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)QuizartinibPhase 3RecruitingPETHEMA Foundation2026-03-18
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaSunitinibPhase 2RecruitingMemorial Sloan Kettering Cancer Center2026-03-17
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical CancerFamitinibNot applicableNot yet recruitingJin LI2026-03-12
MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibSorafenibPhase 3RecruitingThe First Affiliated Hospital of Soochow University2026-03-11
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasPazopanibPhase 1RecruitingM.D. Anderson Cancer Center2026-03-03
FLT3-ITD Targeted Therapy in Fit AML PatientsMidostaurin, QuizartinibPhase 2 / Phase 3Not yet recruitingEuropean Organisation for Research and Treatment of Cancer - EORTC2026-02-23
Imetelstat Combinations in Relapsed AMLMotesanibPhase 1RecruitingDouglas Tremblay2026-01-06
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)Avapritinib—RecruitingBlueprint Medicines Corporation2025-12-04
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyAvapritinib—RecruitingBlueprint Medicines Corporation2025-12-01
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapySunitinibPhase 3RecruitingGlaxoSmithKline2025-10-21
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS PatientsMasitinibPhase 3Not yet recruitingAB Science2025-09-16
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKISunitinibPhase 3Not yet recruitingPeking University Cancer Hospital & Institute2025-09-10
MRD-positive AML Clinical StudyAvapritinibNot applicableRecruitingInstitute of Hematology & Blood Diseases Hospital, China2025-08-20
Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)Ripretinib—Not yet recruitingUniversität Duisburg-Essen2025-08-07
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaPazopanibPhase 2RecruitingImbioray (Hangzhou) Biomedicine Co., Ltd.2025-07-25
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell CarcinomaCM-082Phase 2Active, not recruitingDong Wen2025-07-02
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid LeukemiaAvapritinibPhase 1 / Phase 2RecruitingThe First Affiliated Hospital of Soochow University2025-06-19
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)PazopanibPhase 1 / Phase 2RecruitingTianjin Medical University Second Hospital2025-03-26
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionQuizartinibPhase 2RecruitingDaiichi Sankyo2025-02-13
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or AdolescentsPazopanibPhase 2RecruitingShandong Cancer Hospital and Institute2025-02-10
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTAvapritinibPhase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China2025-01-20
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaQuizartinibPhase 1RecruitingM.D. Anderson Cancer Center2025-01-10
Avapritinib Maintenance for AML With KIT MutationsAvapritinibPhase 2Not yet recruitingRuijin Hospital2025-01-09
Avapritinib Rollover StudyAvapritinibPhase 4RecruitingBlueprint Medicines Corporation2024-12-24
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPazopanibPhase 2RecruitingTianjin Medical University Second Hospital2024-12-18
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentQuizartinibPhase 1RecruitingDaiichi Sankyo2024-12-18
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)PazopanibPhase 3RecruitingSun Yat-sen University2024-12-10
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerTivozanibPhase 3RecruitingAlliance for Clinical Trials in Oncology2024-10-28
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLQuizartinibPhase 3Active, not recruitingDaiichi Sankyo2024-08-29
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsCM-082Phase 1 / Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences2024-08-29
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GISTRipretinibNot applicableRecruitingFirst Affiliated Hospital of Chongqing Medical University2024-07-18
Avapritinib With Decitabine in Patients With SM-AHNAvapritinibPhase 1RecruitingH. Lee Moffitt Cancer Center and Research Institute2024-03-25
Revumenib in Combination With 7+3 + Midostaurin in AMLMidostaurinPhase 1RecruitingRichard Stone, MD2024-03-15
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)SeralutinibPhase 3RecruitingGossamer Bio USA, Inc.2024-02-23
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)PazopanibPhase 3RecruitingIntensity Therapeutics, Inc.2024-02-16
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia PatientsMidostaurinPhase 1RecruitingUniversity Hospital Tuebingen2024-02-09
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyMotesanibPhase 1RecruitingChildren's Oncology Group2024-02-08
Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ FunctionBriquilimabPhase 1 / Phase 2Active, not recruitingNational Heart, Lung, and Blood Institute (NHLBI)2023-11-24
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaTivozanibPhase 2Active, not recruitingM.D. Anderson Cancer Center2023-09-26
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesRipretinibPhase 1 / Phase 2Active, not recruitingDeciphera Pharmaceuticals, LLC2023-07-24
Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 DeficiencyBriquilimabPhase 2Active, not recruitingNational Cancer Institute (NCI)2023-06-18
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibRipretinibPhase 3Active, not recruitingDeciphera Pharmaceuticals, LLC2023-02-17
Drug Screening Using Novel IMD in Renal Cell CarcinomaTivozanibPhase 1RecruitingOliver Jonas2023-01-26
Masitinib in Patients With Mild Alzheimer's DiseaseMasitinibPhase 3Not yet recruitingAB Science2022-10-03
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsTivozanibPhase 1RecruitingArcus Biosciences, Inc.2022-09-10
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsRipretinibPhase 1Active, not recruitingIDRX, Inc., a wholly owned subsidiary of GSK, LLC2022-08-05
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisMotesanibPhase 1Active, not recruitingGeron Corporation2022-05-12
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaBriquilimabPhase 1 / Phase 2Active, not recruitingNational Heart, Lung, and Blood Institute (NHLBI)2022-05-03
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesTivozanibPhase 1 / Phase 2RecruitingUniversity of Florida2021-08-11
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing BriquilimabBriquilimabPhase 1 / Phase 2RecruitingPorteus, Matthew, MD2021-03-05
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)Midostaurin—RecruitingAcute Leukemia French Association2021-03-02
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)2021-02-05
TDM for Optimized Outcome in Patients With mRCC.Tivozanib—RecruitingNiels Fristrup2020-12-09
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersTivozanibPhase 1 / Phase 2RecruitingNational Cancer Institute (NCI)2020-11-27
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentMotesanibPhase 3Active, not recruitingGeron Corporation2020-10-06
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTPexidartinibPhase 3Active, not recruitingDaiichi Sankyo Co., Ltd.2020-07-28
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerCediranibPhase 2Active, not recruitingThe Clatterbridge Cancer Centre NHS Foundation Trust2020-07-27
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)MidostaurinPhase 1 / Phase 2RecruitingTechnische Universität Dresden2020-05-12
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS PatientsMidostaurinPhase 2Active, not recruitingStichting Hemato-Oncologie voor Volwassenen Nederland2019-09-20
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerCediranibPhase 2RecruitingM.D. Anderson Cancer Center2019-09-16
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsCediranibPhase 2Active, not recruitingUniversity Health Network, Toronto2019-02-22
WIRE - Novel Treatments in Renal Cell CancerCediranibPhase 2RecruitingCCTU- Cancer Theme2018-11-14
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibRipretinibPhase 3Active, not recruitingDeciphera Pharmaceuticals, LLC2018-09-17
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)2018-09-07
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyCediranibPhase 2Active, not recruitingAstraZeneca2017-11-07
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsMasitinibPhase 3RecruitingAB Science2017-04-25
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)2016-11-28
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)MotesanibPhase 2 / Phase 3Active, not recruitingGeron Corporation2015-11-06
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...PexidartinibPhase 1RecruitingNational Cancer Institute (NCI)2015-03-18
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPexidartinibPhase 2RecruitingQuantumLeap Healthcare Collaborative2010-01-05

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Piebaldism
0.82
Cutaneous mastocytosis
0.81
Mastocytosis
0.66
Cancer
0.66
Neoplasm
0.63

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
KIT

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1936, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P10721, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.